EpilepsyGTx und Viralgen arbeiten gemeinsam daran, das AAV-Gentherapieprogramm zur Behandlung von Epilepsie im Vorfeld der ersten klinischen Studie am Menschen voranzutreiben

PartnershipEPY201Positive

AI Analysis

Summary

EpilepsyGTx and Viralgen have entered into a partnership to advance EPY201, an AAV gene therapy for focal refractory epilepsy, ahead of first-in-human clinical studies. The collaboration will focus on scalable manufacturing of the therapy to treat a patient population of approximately 10 million people.

Clinical Trial Data

Outcome Details

Collaboration to advance AAV gene therapy program ahead of first clinical trial in humans; manufacturing partnership for scalable EPY201 production

Importance:6/10

Sentiment:

0.60

Gene TherapyAAVEpilepsyCDMO PartnershipManufacturingClinical Development

Read the original article

Published by PR Newswire Biotech on September 9, 2026 8:40 AM

Read Original